Myriad Genetics, Inc’s recently made public that its President and CEO DIAZ PAUL J unloaded Company’s shares for reported $0.34 million on Oct 11 ’24. In the deal valued at $22.93 per share,15,000 shares were sold. As a result of this transaction, DIAZ PAUL J now holds 962,378 shares worth roughly $13.12 million.
Then, DIAZ PAUL J bought 15,000 shares, generating $343,950 in total proceeds.
Before that, Ancona Margaret bought 11,538 shares. Myriad Genetics, Inc shares valued at $321,019 were divested by the Officer at a price of $27.82 per share.
UBS initiated its Myriad Genetics, Inc [MYGN] rating to a Neutral in a research note published on December 10, 2024; the price target was $18. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who decreased its forecast for the stock in early December from “an Outperform” to “a Market perform”. Morgan Stanley began covering MYGN with “an Equal-weight” recommendation on September 19, 2024. Wells Fargo started covering the stock on August 28, 2024. It rated MYGN as “an Overweight”.
Price Performance Review of MYGN
On Monday, Myriad Genetics, Inc [NASDAQ:MYGN] saw its stock jump 1.56% to $13.63. Over the last five days, the stock has gained 2.02%. Myriad Genetics, Inc shares have fallen nearly -28.79% since the year began. Nevertheless, the stocks have fallen -30.88% over the past one year. While a 52-week high of $29.30 was reached on 09/18/24, a 52-week low of $12.87 was recorded on 12/19/24. SMA at 50 days reached $16.81, while 200 days put it at $22.50.
Levels Of Support And Resistance For MYGN Stock
The 24-hour chart illustrates a support level at 13.17, which if violated will result in even more drops to 12.71. On the upside, there is a resistance level at 13.96. A further resistance level may holdings at 14.29. The Relative Strength Index (RSI) on the 14-day chart is 33.11, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.37, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.26%. Stochastics %K at 21.53% indicates the stock is a holding.
How much short interest is there in Myriad Genetics, Inc?
A steep rise in short interest was recorded in Myriad Genetics, Inc stocks on 2024-12-13, dropping by -0.34 million shares to a total of 3.35 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 3.69 million shares. There was a decline of -10.28%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 27, 2024 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating along with a $29 price target.
